2025 Medicare Advantage Year-in-Review

2025 was a transitional, high-pressure year for Medicare Advantage marked by sustained margin compression, strategic recalibration, and a sharp divergence in growth segments — particularly within Special Needs Plans (SNPs). Margin pressure intensified across most MA-focused carriers for a second consecutive year. Consistently high utilization, risk‑score headwinds, and elevated pharmacy expenses and volatility precipitated by the Inflation Reduction Act pushed MLRs above targets. Many carriers revised guidance, took impairments, and, crucially, began pivoting toward a strategy of retrenchment rather than a rebound.

Stars headwinds deepened financial strain

Star Ratings intensified this pressure. Maintaining 4+ Stars became more challenging as the CMS adjusted cutpoints and tightened methodology, reducing the weight of member experience measures while shifting greater emphasis toward clinical and outcome-based measures. Many contracts lost bonus-eligible status, compounding margin strain and accelerating product pruning, benefit reductions, and selective market exits.

Leaner product landscape, but stable access

CMS data show 2026 will be one of the highest plan exit years in recent history, including full terminations and service area reductions forcing more members to shop and disrupting distribution. Roughly 2.9 million enrollees will be impacted by plan exits and service area reductions in 2026, representing about 10% of MA members nationwide. MA carriers also materially expanded noncommissioned plans for 2025 and 2026, shrinking income opportunities for agents and further complicating enrollee choice in some markets.

Despite this contraction, beneficiary access remained broad: Most enrollees still had dozens of MA options, nearly universal access to at least one $0 premium MAPD plan, and continued coverage of core supplemental benefits. The 2026 Rate Announcement then delivered the first real tailwind in years, with a meaningful funding increase that improved the outlook for 2026 bids and signaled CMS’s intent to keep MA attractive.

Diverging SNP trajectories signal a market shift

C-SNPs also emerged as a breakout growth engine, creating opportunities for better cost alignment, stronger economics, and scalable care coordination models. D-SNP growth, by contrast, flattened amid tighter state integration rules and Medicaid redeterminations. This C-SNP/D-SNP divergence, alongside a leaner, more targeted 2026 product landscape, paints a picture of an industry in managed recalibration: fewer, more sustainable plans and continued financial strain, yet stable access and a clear shift toward complex, high-need populations.

Looking ahead to 2026 and beyond

In the wake of these recalibrations, provider success in Medicare Advantage will be defined by the ability to perform in shared-risk arrangements through disciplined care management, accurate and timely diagnosis, Stars-oriented clinical performance, and tight control of avoidable utilization. In practice, this means building repeatable workflows for care gap closure, deploying data that clinicians can act on in real time, aligning incentives across clinical and administrative teams, and partnering with organizations that can enable these capabilities without requiring providers to become health plans themselves.

There are several reasons for optimism for provider organizations and health systems that can adapt to this new landscape:

Funding tailwinds and more sustainable product mix

The 2026 Rate Announcement delivered the first meaningful MA funding boost in recent memory, easing two years of intense margin compression and giving plans room to stabilize benefits, strengthen Stars strategies, and reinvest in care models. Carriers are also aggressively trimming marginal products (especially unprofitable PPOs, MA-only, and weak Stars contracts) and exiting structurally unattractive markets — recentering portfolios on geographies, benefits, and segments where revenue and costs can be better aligned.

From a provider perspective, this more disciplined product environment raises the value of execution over scale. As carriers concentrate capital and membership into fewer, more intentional offerings, they increasingly depend on provider partners that can deliver consistent clinical performance, accurate risk documentation, and predictable utilization management — turning incremental funding improvements into durable margin and quality gains rather than short-lived relief.

Shift toward segments and models where risk can be managed

The rapid growth in C-SNPs reflects a pivot to populations where targeted care management, tighter networks, and value-based payer/provider partnerships can more reliably translate into financial and clinical performance.

For provider groups and health systems, this creates a larger pipeline of members in arrangements explicitly designed for intensive care coordination, stronger data exchange, and aligned incentives — improving the likelihood of earning shared savings and performance bonuses. To capture these opportunities, providers must be able to identify high-risk members early, deploy longitudinal care management programs, and ensure accurate, compliant clinical documentation at the point of care. Just as importantly, they must do so in a way that integrates with existing workflows and does not require providers to build payer-grade infrastructure from scratch.

Stars and policy changes favor clinically strong, integrated operators

CMS’s evolving Stars methodology — with its greater emphasis on clinical and outcome measures — and Part D redesign are challenging in the short run, but they structurally reward plans and providers that effectively manage utilization, close care gaps, and integrate behavioral and medical care. As benefit-driven competition among carriers recedes, plans and risk-bearing providers with robust clinical infrastructure, data capabilities, and value-based partnerships stand to capture share, stabilize margins, and build a more durable, quality-linked economic model in 2026 and beyond.

As MA enters 2026, the industry is moving toward equilibrium: fewer plans, more intentional strategies, stronger alignment between cost and care, and accelerated focus on complex, high-need members. Success will increasingly hinge on clinical strength, Stars excellence, and meaningful payer–provider collaboration, setting the stage for a more durable, value-anchored MA market ahead.

Organizations that invest now in Stars strategy, care integration, and risk alignment — whether through internal restructuring or integrated enablement partnerships — will be best positioned to capitalize on this future stability, while those that wait will be reacting to the market rather than helping to shape it.